Abstract:Therapeutic resistance is the major barrier to conquer human cancer, the most lethal pathology that claims numerous lives per year. Although identification of resistance mechanisms is the key to develop optimal strategies, progress has been limited due to long term failure to reveal the most critical targets. Cancer cells exhibit high plasticity even in clinical settings, a phenomenon that contributes to disease refraction by developing intrinsic or acquired resistance. Here we highlight the multifaceted and genetically conserved senescence-associated secretory phenotype (SASP), which encodes a large array of soluble factors including amphiregulin (AREG). Expression of AREG is markedly inducible by DNA damage to stromal cells in the tumor microenvironment (TME), a process mediated predominantly by the NF-κB complex and C/EBP family. Stromal AREG remarkably enhances the malignancy of cancer cells including acquired resistance, mainly by activating the EGFR pathway and causing a distinct epithelial to endothelial transition (EET). Paracrine AREG induces PD-L1 expression in recipient cancer cells, thereby creating an immunosuppressive TME via immune checkpoint activation. Therapeutic targeting AREG by a monoclonal antibody not only remarkably deprived cancer cells of chemoresistance, but achieved prominent efficiency when combined with classical chemotherapy in humanized animals with restored immunocompetency. Stromal AREG enters circulation and is readily detectable in the peripheral blood of post-treatment patients, representing a novel liquid biopsy biomarker for therapeutic evaluation and disease prognosis. Our study substantiates the potential of in vivo SASP in driving the TME-mediated drug resistance and shaping an immunosuppressive niche, and provides the proof-of-principle of targeting major SASP factors to effectively improve therapeutic index with reduced mortality. Citation Format: Qixia Xu, Jean-Philippe Coppé, Judith Campisi, Eric Lam, Yu Sun. Amphiregulin in damaged tumor microenvironment potentiates therapeutic resistance and enables PD-L1-mediated immunosuppression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3819.

A Mediator Lost in the War on Cancer

MED12 Controls the Response to Multiple Cancer Drugs Through Regulation of TGF-β Receptor Signaling.

Abstract PR12: MED12 Methylation by CARM1 Sensitizes Human Breast Cancer Cells to Chemotherapy Drugs

MED12 Methylation by CARM1 Sensitizes Human Breast Cancer Cells to Chemotherapy Drugs

Mediator Complex Subunit 16 is Down-Regulated in Papillary Thyroid Cancer, Leading to Increased Transforming Growth Factor-Β Signaling and Radioiodine Resistance

Enhanced T cell effector activity by targeting the Mediator kinase module

Abstract LT04: Dissecting Mediator Kinase Activity in Normal Tissue Homeostasis and Cancer

MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer

MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC

Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer

TGF-β Signaling and Resistance to Cancer Therapy

Mediator Subunit Med4 Enforces Metastatic Dormancy in Breast Cancer

MED16 Promotes Tumour Progression and Tamoxifen Sensitivity by Modulating Autophagy Through the Mtor Signalling Pathway in ER-Positive Breast Cancer

Phosphorylated MED1 links transcription recycling and cancer growth

Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis

Mediator Subunit 23 Overexpression As A Novel Target for Suppressing Proliferation and Tumorigenesis in Hepatocellular Carcinoma

Interaction Between MED12 and ΔNp63 Activates Basal Identity in Pancreatic Ductal Adenocarcinoma

A C->T Variation in 3'-Untranslated Region Elevates MED12 Protein Level in Breast Cancer That Relates to Better Prognosis

Abstract 3819: Amphiregulin in Damaged Tumor Microenvironment Potentiates Therapeutic Resistance and Enables PD-L1-mediated Immunosuppression

Transition to Resistance: an Unexpected Role of the EMT in Cancer Chemoresistance